Outlook TherapeuticsOTLK +6.21%11 Gross Margin % is -17.32% as of Mar. 2026. GuruFocus rates OTLK with a GF Score™ of 11/100. The stock has 6 warning signs investors should review. Among 736 Biotechnology companies, Outlook Therapeutics ranks worse than 97.83% on this metric.
The historical rank and industry rank for Outlook Therapeutics's Gross Margin % or its related term are showing as below:
OTLK'
s Gross Margin % Range Over the Past 10 Years
Min: -361.75 Med: 4.03 Max: 4.03
Current: -361.75
During the past 12 years, the highestGross Margin % of Outlook Therapeutics was 4.03%. The lowest was -361.75%. And the median was 4.03%.
OTLK's Gross Margin % is ranked worse than 97.83% of 736
companies
in the Biotechnology industry
Industry Median: 60.91
vs OTLK: -361.75
Outlook Therapeutics had a gross margin of -17.32% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Outlook Therapeutics was 0.00% per year.
Outlook Therapeutics (NAS:OTLK) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Outlook Therapeutics had a gross margin of -17.32% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Outlook Therapeutics Gross Margin % Related Terms
Outlook Therapeutics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Outlook Therapeutics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OTLK vs INO, CBUS, RANI: Gross Margin % Comparison
For the Biotechnology subindustry, Outlook Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Outlook Therapeutics Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Outlook Therapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Outlook Therapeutics (OTLK) has a Gross Margin % of -17.32% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Outlook Therapeutics and its competitors. According to the industry distribution chart, Outlook Therapeutics ranks #720 out of 736 companies in the Biotechnology industry, placing it in the top 97.8%.
Is Outlook Therapeutics' Gross Margin % too high?
Outlook Therapeutics' current Gross Margin % is -17.32%. Based on the distribution chart, Outlook Therapeutics ranks #720 out of 736 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Outlook Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Outlook Therapeutics' Gross Margin % compare to INO and CBUS?
According to the Biotechnology industry distribution chart, Outlook Therapeutics ranks #720 out of 736 companies for Gross Margin %. This places Outlook Therapeutics in the lower half of its industry. The industry median Gross Margin % is 60.91. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Outlook Therapeutics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Outlook Therapeutics's current Gross Margin % is -17.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Outlook Therapeutics stock overvalued right now?
Outlook Therapeutics (OTLK) has a current Gross Margin % of -17.32%. The current Gross Margin % is -17.32%. Outlook Therapeutics' overall GF Score™ is 11/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Outlook Therapeutics (OTLK), the current Gross Margin % is -17.32% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
11GF Score
Get the complete analysis for OTLK
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OTLK has been successfully added to your 
